Invention Grant
- Patent Title: Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
-
Application No.: US15936686Application Date: 2018-03-27
-
Publication No.: US10280209B2Publication Date: 2019-05-07
- Inventor: Raymond Kaempfer , Anat Shirvan , Gila Arad
- Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD , ATOX BIO LTD.
- Applicant Address: IL Ness Ziona IL Jerusalem
- Assignee: ATOX BIO LTD.,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
- Current Assignee: ATOX BIO LTD.,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
- Current Assignee Address: IL Ness Ziona IL Jerusalem
- Agency: Browdy and Neimark, PLLC
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K38/17 ; A61K45/06 ; A61K38/00

Abstract:
The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
Public/Granted literature
- US20180215804A1 REDUCTION OF INFLAMMATORY DISEASE SYMPTOMS BY SHORT PEPTIDES THAT INHIBIT SIGNALING THROUGH CD28 Public/Granted day:2018-08-02
Information query